Biogen Inc. today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer.
“Chuck will bring invaluable industry insights and a strong network of relationships to Biogen, and I’m pleased to welcome him to our leadership team,” said Michael McDonnell, Executive Vice President and Chief Financial Officer. “His wealth of experience collaborating with company leaders through periods of strong growth and transition will enhance our continuous efforts to inform investors on our go-forward strategy as we work on our path to sustainable growth.”
Mr. Triano brings over 35 years of financial experience to the role, having held executive positions across prominent biotechnology and pharmaceutical companies over the last two decades, most recently as Chief Financial Officer for Xalud Therapeutics.
Prior to joining Xalud Therapeutics, Mr. Triano served as Senior Vice President of Investor Relations at Pfizer for over a decade, where he was responsible for all global investor relations functions, as well as operations planning and analysis. Previously, he served as the Vice President of Investor Relations at Forest Laboratories, where he initiated the company’s first formal investor relations and corporate communications program. He was also a managing director at The Carson Group, a financial information organization specializing in global shareholder research and capital markets intelligence. He holds a bachelor’s degree from the University of Connecticut.
Mike Hencke, Executive Director, Investor Relations, and the Investor Relations team will report to Mr. Triano.
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.